lucatumumab
patritumab
-umab
atezolizumab
agonistic monoclonal antibody
antigenomic
intrabody
cibisatamab
alloantibody
reagin
teplizumab
dorlixizumab
sulesomab
conatumumab
chromobody
biciromab
immunonaive
siltuximab
robatumumab
antiantibody
zolimomab
panitumumab
-a-
presentation
monoclonal
drozitumab
olendalizumab
oleclumab
heterophil antibody
-ab
heterophile antibody
Forssman antibody
iratumumab
polyantibody
idiospecific
onartuzumab
pancytokeratin
properdin
complement
dacetuzumab
polyvalent
sifalimumab
antiustekinumab
-i-
immunoprobe
bezlotoxumab
Ab
brentuximab
lenzilumab
polytypic